Compare American Water Works Company Inc (AWK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Water Works Company Inc vs TG Therapeutics Inc — how do they compare? American Water Works Company Inc trades at $131.69 (market cap $25.69B), while TG Therapeutics Inc trades at $54.84 (market cap $8.41B). The key difference: American Water Works Company Inc is far larger — about 3.1× TG Therapeutics Inc's market cap, and American Water Works Company Inc pays a 2.72% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AWK | TGTX | |
|---|---|---|
Market Cap | $25.69B | $8.41B |
Sector | Utilities | Health |
52-Week High | $147.00 | $59.06 |
52-Week Low | $121.13 | $26.39 |
Enterprise Value | $41.25B | $8.65B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Water Works (AWK) trades at $131.53, up 0.64% with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth from $3.8B in 2022 to $5.14B in 2025, maintaining net margins above 21%. Recent earnings show mixed results with a Q3 2025 beat but Q1 2026 miss, while the company continues infrastructure investments and community initiatives.
AWK presents a stable utility investment with moderate upside to the $137 consensus target. Key risks include regulatory approvals for rate increases and high capital expenditures. Analyst sentiment is balanced with 47% buy ratings, though recent earnings misses warrant caution ahead of Q2 2026 results on July 29, 2026.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
